Two years after successfully suing the US FDA to enable communications about the off-label use of Vascepa (icosapent ethyl), Amarin Corp. PLC is again seeking an unusual route in trying to protect its market for the triglyceride-lowering agent – by asking the International Trade Commission (ITC) to block unapproved drugs "cloaked" as dietary supplements.
Amarin is requesting an ITC investigation "into the unlawful importation or sale" in the US of synthetically produced omega-3 products...





